Clinical Trial Update: Long-term Safety and Tolerability of Iptacopan in Patients With Paroxysmal Nocturnal Hemoglobinuria [Phase 3]

View source ↗

Summary

An ongoing Phase 3 trial is evaluating the long-term safety and tolerability of iptacopan in patients with paroxysmal nocturnal hemoglobinuria.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Paroxysmal Nocturnal Hemoglobinuria

Drugs mentioned

• iptacopan (iptacopan)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Paroxysmal Nocturnal Hemoglobinuria | Phase 3 | Status: ACTIVE_NOT_RECRUITING